Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
8
pubmed:dateCreated
2005-8-11
pubmed:abstractText
Murine double minute 2 (MDM2) inhibits p53-mediated functions, which are essential for therapies using DNA-damaging agents. The purpose of this study was to determine whether MDM2 inhibition enhances the radiosensitivity of a lung cancer model. The effects of MDM2 inhibition on tumor vasculature were also studied. Transient transfection of H460 lung cancer cells and human umbilical vascular endothelial cells (HUVEC) with antisense oligonucleotides (ASODN) against MDM2 resulted in a reduced level of MDM2 and increased levels of p21 and p53. Clonogenic assays showed that inhibition of MDM2 greatly decreased cell survival following irradiation. Quantification of apoptotic cells by 7-aminoactinomycin D staining and of senescent cells by X-gal staining showed that both processes were significantly increased in H460 cells treated with MDM2-specific ASODN and radiation. H460 xenografts that were treated with MDM2 ASODN plus radiotherapy also showed significant growth delay (P < 0.001) and increased apoptosis by terminal deoxynucleotidyl transferase-mediated nick end labeling staining. HUVECs transfected with MDM2-specific ASODN showed impaired viability and migration with decreased tube formation. Doppler studies showed that tumor blood flow was compromised when H460 xenografts were treated with MDM2-specific ASODN and radiation. A combination of radiotherapy and inhibition of MDM2 through the antisense approach results in improved tumor control in the H460 lung cancer model. This implies that a similar strategy should be investigated among patients with locally advanced lung cancer, receiving thoracic radiotherapy.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/CDKN1A protein, human, http://linkedlifedata.com/resource/pubmed/chemical/Cdkn1a protein, mouse, http://linkedlifedata.com/resource/pubmed/chemical/Cell Cycle Proteins, http://linkedlifedata.com/resource/pubmed/chemical/Cyclin-Dependent Kinase Inhibitor..., http://linkedlifedata.com/resource/pubmed/chemical/MDM2 protein, human, http://linkedlifedata.com/resource/pubmed/chemical/Mdm2 protein, mouse, http://linkedlifedata.com/resource/pubmed/chemical/Nuclear Proteins, http://linkedlifedata.com/resource/pubmed/chemical/Oligonucleotides, Antisense, http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins, http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins c-mdm2, http://linkedlifedata.com/resource/pubmed/chemical/Radiation-Sensitizing Agents, http://linkedlifedata.com/resource/pubmed/chemical/Tumor Suppressor Protein p53
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
1535-7163
pubmed:author
pubmed:issnType
Print
pubmed:volume
4
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1137-45
pubmed:dateRevised
2007-11-14
pubmed:meshHeading
pubmed-meshheading:16093429-Animals, pubmed-meshheading:16093429-Apoptosis, pubmed-meshheading:16093429-Cell Aging, pubmed-meshheading:16093429-Cell Cycle Proteins, pubmed-meshheading:16093429-Cyclin-Dependent Kinase Inhibitor p21, pubmed-meshheading:16093429-Endothelium, Vascular, pubmed-meshheading:16093429-Humans, pubmed-meshheading:16093429-Lung Neoplasms, pubmed-meshheading:16093429-Mice, pubmed-meshheading:16093429-Nuclear Proteins, pubmed-meshheading:16093429-Oligonucleotides, Antisense, pubmed-meshheading:16093429-Proto-Oncogene Proteins, pubmed-meshheading:16093429-Proto-Oncogene Proteins c-mdm2, pubmed-meshheading:16093429-Radiation-Sensitizing Agents, pubmed-meshheading:16093429-Transfection, pubmed-meshheading:16093429-Tumor Cells, Cultured, pubmed-meshheading:16093429-Tumor Suppressor Protein p53, pubmed-meshheading:16093429-Umbilical Cord, pubmed-meshheading:16093429-Up-Regulation
pubmed:year
2005
pubmed:articleTitle
Murine double minute 2 as a therapeutic target for radiation sensitization of lung cancer.
pubmed:affiliation
Department of Radiation Oncology, Vanderbilt University, 1301 22nd Avenue South, B-902 The Vanderbilt Clinic, Nashville, TN 37232-5671, USA.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural